Company intelligence / Profile preview

Arpeggio Biosciences

Ownership: Private
Development stage: Preclinical

Overview

Preclinical data show promising activity such as regression of aggressive adenocarcinoma tumors via an NRF2 degrader in vivo; significant tumor growth inhibition with GPX4 inhibitors; prevention of renal injury in mice models; neuronal cell death prevention in microglia models

Therapeutic areas: NeurologyOncologyNephrology
Modalities: Small moleculesBiological productsChemical drugsTranscriptomic sequencing-based drug discovery platform
Industry: Biotech

Drug pipeline

1 asset

ARP-4922

Preclinical

Partnerships

Builders VC (lead Series A investor)[5]Khosla Ventures[5]TechU Ventures[5]FundersClub[5]Tencent[5]Formic Ventures[5]Tau Ventures[5]Milad Alucozai/BoxOne Ventures [5]Matthew De Silva/Longtail Capital [5]FORMA Therapeutics collaboration to explore translational utility of drug candidates [8]

Beyond the preview

Go deeper on Arpeggio Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arpeggio Biosciences.

Explore the full profile